News & Events about Arcus Biosciences Inc.
Arcus Biosciences, Inc. (NYSE:RCUS Get Rating) has been given a consensus recommendation of Moderate Buy by the ten research firms that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on ...
Arcus Biosciences, Inc. (NYSE:RCUS Get Rating) has been assigned an average recommendation of Moderate Buy from the nine ratings firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold rating and seven have given a ...
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Companys Board of Directors granted four new employees options to purchase a total of 11,250 shares of the...
MarketWatch.com - GOOG
2years ago
New data on a cancer drug trial from Gilead Sciences and Arcus Biosciences are resurfacing debate around the class of cancer drugs known as anti-TIGITs...
Shares of Arcus Biosciences, Inc. (NYSE:RCUS Get Rating) have been given an average rating of Moderate Buy by the nine brokerages that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and six have issued a buy ...